Day: September 5, 2024

Collaboration with World Leading University, University of Edinburgh Multi-Million Dollar Transformative Project for Long-Term Care Future Partnering OpportunitiesVANCOUVER, British Columbia, Sept. 05, 2024 (GLOBE NEWSWIRE) — Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with the University Court of the University of Edinburgh (“University of Edinburgh”). The University of Edinburgh is looking to utilize Treatment’s proprietary Global Library of Medicine (“GLM”) to jointly build applications within the “SET4 Systems Engineering to Transform Transitions In Health and Social Care innovation initiative” (“SET4”). World Leading University Treatment is partnering with the University of Edinburgh, recently acknowledged as amongst the world’s...

The company presents the received notifications regarding the loss of votes and the acquisition of directly held votes (a purchase-sale transaction within the „Invalda INVL“ group).   The person authorized to provide additional information:Kazimieras TonkūnasINVL Technology Managing Partnere-mail k.tonkunas@invltechnology.ltAttachmentsINC1L_disposal of voting rights by INVL Life_2024 09 04INC1L_acquisition of voting rights by Invalda INVL_2024 09 04

SAMPO PLC                 STOCK EXCHANGE RELEASE                  5 September 2024 at 8:30 am Sampo plc’s share buybacks 4 September 2024 On 4 September 2024, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  4,078 40.69 AQEU          36,224 40.68 CEUX  1,413 40.70 TQEX  54,498 40.68 XHELTOTAL 96,213 40.68  *rounded to two decimals                 On 17 June 2024, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which...

Kaspars BeitiņšKaspars BeitiņšKaspars Beitiņš, who was responsible for the design, construction and opening of the shopping center “AKROPOLE Rīga” in the period from 2012 to 2019, has been appointed as the new CEO and member of the board of SIA “Akropole Rīga”.  SIA “Akropole Riga” is a subsidiary of “Akropolis Group”, through which    shopping centers “AKROPOLE Rīga” and “AKROPOLE Alfa” are managed. For the past five years, K. Beitiņš headed the real estate development company SIA “Galio Development”, which he will continue to head in the future. “By introducing changes in the management structure of SIA “Akropole Rīga”, we want to strengthen our local management team, and this decision shows how important business development in Latvia is to “Akropolis Group”....

WISeKey Presents Digital Transformation Initiatives at APBA Event in Spain  Algeciras, Spain – September 5, 2024: WISeKey International Holding Ltd. (“WISeKey” or “Company”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, digital identity, and Internet of Things (IoT) company, participated in a key event at La Autoridad Portuaria de la Bahía de Algeciras (APBA) under the theme “Upcoming Digital Entrepreneurship Initiatives in the Campo de Gibraltar.” The event, held in collaboration with WISeKey as a member of the Algeciras Port Innovation Committee, aimed to showcase various initiatives related to digital transformation in the Campo de Gibraltar region. The event highlighted three major projects: 1. The RETECH Program at the Port of Algeciras. 2. The future Industry 4.0 Hub in La Línea de la Concepción. 3. The...

The management board of EfTEN Real Estate Fund AS presented to the supervisory board a proposal for issuing new shares, the purpose of which is to finance new planned acquisitions. The volume of the issue is initially planned to be 10% of the fund’s current equity capital (approximately 20 million euros), which in case of oversubscription can be upsized to 15% of the fund’s equity capital (approximately 30 million euros). The fund is considering issuing new shares at a price that corresponds to the 60-day simple average closing price of the fund’s shares on the Nasdaq Tallinn stock exchange. In addition to offering shares in Estonia, offering shares in Latvia and Lithuania is also being considered. The new shares are planned to be listed on the Nasdaq Tallinn stock exchange. The management board of the fund sees that...

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Halle (Saale) / Munich, Germany, September 5, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will host two events in September:Half year 2024 results on September 12; webcast at 3pm CEST Virtual Kidney Disease KOL event on September 30, 2024; webcast at 3pm CESTHalf Year 2024 ResultsVivoryon will publish its financial results for the half year 2024 and provide a corporate update on Thursday, September 12, 2024. The Company will host a conference call and webcast open to...

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion,...